このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gufic Biosciences マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Pranav Choksi

最高経営責任者

₹2.0m

報酬総額

CEO給与比率	98.1%
CEO在任期間	20yrs
CEOの所有権	7.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	7.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Gufic Biosciences の収益と比較して、Pranav Choksi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	₹861m
Dec 31 2023	n/a	n/a	₹842m
Sep 30 2023	n/a	n/a	₹823m
Jun 30 2023	n/a	n/a	₹793m
Mar 31 2023	₹2m	₹2m	₹797m
Dec 31 2022	n/a	n/a	₹819m
Sep 30 2022	n/a	n/a	₹826m
Jun 30 2022	n/a	n/a	₹857m
Mar 31 2022	₹2m	₹2m	₹958m
Dec 31 2021	n/a	n/a	₹884m
Sep 30 2021	n/a	n/a	₹829m
Jun 30 2021	n/a	n/a	₹769m
Mar 31 2021	₹6m	₹2m	₹442m
Dec 31 2020	n/a	n/a	₹305m
Sep 30 2020	n/a	n/a	₹243m
Jun 30 2020	n/a	n/a	₹123m
Mar 31 2020	₹5m	₹2m	₹227m
Dec 31 2019	n/a	n/a	₹243m
Sep 30 2019	n/a	n/a	₹232m
Jun 30 2019	n/a	n/a	₹249m
Mar 31 2019	₹2m	₹2m	₹219m
Dec 31 2018	n/a	n/a	₹164m
Sep 30 2018	n/a	n/a	₹168m
Jun 30 2018	n/a	n/a	₹164m
Mar 31 2018	₹2m	₹2m	₹165m

報酬と市場: Pranavの総報酬 ($USD 24.43K ) は、 Indian市場 ($USD 275.31K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Pranavの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Pranav Choksi (41 yo)

20yrs

在職期間

₹2,040,900

報酬

Mr. Pranav Jayesh Choksi has been an Executive Whole Time Director of Gufic Biosciences Ltd. since June 25, 2004 and serves as its Chief Executive Officer. Mr. Choksi serves as Chief Executive Officer & Wh...

取締役

名称	ポジション	在職期間	報酬	所有権
Jayesh Choksi	Chairman & MD	24.8yrs	₹4.04m	24.62% ₹ 8.8b
Pranav Choksi	CEO & Whole Time Director	20yrs	₹2.04m	7.25% ₹ 2.6b
Pankaj Gandhi	Whole-Time Director	10.8yrs	₹1.59m	データなし
Dilip Ghosh	Additional Whole Time Director	3.6yrs	₹2.14m	0.072% ₹ 25.8m
Shreyas Patel	Non Executive Independent Director	9.8yrs	₹70.00k	0.0026% ₹ 930.2k
Gopal Daptari	Independent Director	7.6yrs	₹70.00k	データなし
Balram Singh	Non-Executive & Non Independent Director	6.1yrs	データなし	データなし
Rabi Sahoo	Non-Executive Independent Director	5yrs	₹50.00k	データなし
Anu Aurora	Independent Director	4.5yrs	₹70.00k	データなし

7.6yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: 509079の取締役会は経験豊富であると考えられます ( 7.6年の平均在任期間)。

Gufic Biosciences マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Insufficient new directors

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Recent updates

Investor sentiment improves as stock rises 19%

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Investor sentiment improves as stock rises 18%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

Upcoming dividend of ₹0.10 per share

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: ₹109

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹132

Second quarter 2021 earnings released: EPS ₹2.10

Market bids up stock over the past week

Market bids up stock over the past week

New 90-day high: ₹103

Upcoming Dividend of ₹0.05 Per Share

First quarter earnings released

Full year earnings released - EPS ₹2.94

Gufic Biosciences Limited to Report Q4, 2020 Results on Jul 31, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34